Condition

Head and Neck Squamous Cell Carcinoma (HNSCC)

ClinicalTrials.gov condition label

Clinical trials13

Recruiting6

Common interventions25

Lead sponsors shown12

Clinical trials

13 shown

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198 · 2026-04-13

RECRUITING

AK129 Combination Therapy for Advanced Solid TumorsNCT06943820 · 2025-05-21

RECRUITING

A Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · 2025-04-18

RECRUITING

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected MalignanciesNCT05473156 · 2023-07-24

RECRUITING

Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655 · 2023-07-06

RECRUITING

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14

RECRUITING

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171 · 2023-10-13

ACTIVE_NOT_RECRUITING

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)NCT04220866 · 2020-03-04

COMPLETED

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsNCT04215978 · 2020-01-30

COMPLETED

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsNCT04083599 · 2019-09-17

ACTIVE_NOT_RECRUITING

A Phase 1 Study of [225Ac]-FPI-1434 InjectionNCT03746431 · 2019-01-17

TERMINATED

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsNCT03811652 · 2018-12-20

COMPLETED

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsNCT03735628 · 2018-10-17

COMPLETED

Common interventions

CarboplatinDRUG2DocetaxelDRUG2NivolumabDRUG2PaclitaxelDRUG2PemetrexedDRUG2[111In]-FPI-1547 InjectionDRUG1[225Ac]-FPI-1434 Injection multi-doseDRUG1[225Ac]-FPI-1434 Injection single-doseDRUG15-FUDRUG15-FU (5-fluorouracil)DRUG1AB598DRUG1AK129(dose 1)DRUG1AK129(dose 2)DRUG1AK129(RP2D)DRUG1AP203DRUG1BGB-A445DRUG1CetuximabDRUG1ChemotherapyDRUG1Cis-platinumDRUG1CisplatinDRUG1CopanlisibDRUG1DDI Probe CocktailDRUG1EXS74539DRUG1FluorouracilDRUG1FPI-1175 InfusionBIOLOGICAL1

Leading sponsors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.2Akeso1AP Biosciences Inc.1Arcus Biosciences, Inc.1Bayer1BeiGene1Exelixis1Fusion Pharmaceuticals Inc.1Genmab1MedImmune LLC1Merck Sharp & Dohme LLC1Tanabe Pharma America, Inc.1

Trial status mix

RECRUITING6

COMPLETED4

ACTIVE_NOT_RECRUITING2

TERMINATED1

Phase mix

PHASE112

PHASE26

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.